News & Updates
Filter by Specialty:
Cardiorenal benefit with investigational GLP-1 RA independent of concurrent SGLT2 inhibitor
30 Nov 2021
byJairia Dela Cruz
The glucagon-like peptide-1 receptor agonist (GLP-1 RA) efpeglenatide affords cardiovascular and renal protection that is not explained by concurrent use of a sodium-glucose co-transporter-2 (SGLT2) inhibitor in patients with type 2 diabetes (T2D), according to an exploratory analysis of AMPLITUDE-O.
Cardiorenal benefit with investigational GLP-1 RA independent of concurrent SGLT2 inhibitor
30 Nov 2021
Repurposing a broad-spectrum antiviral drug may help treat asymptomatic, mild COVID-19
29 Nov 2021
byJairia Dela Cruz
The oral antiviral drug umifenovir, which is used to treat influenza, appears to be beneficial in COVID-19 patients who are asymptomatic or with mild symptoms, with a phase III study showing that the drug is well tolerated and can induce viral clearance within 5 days.